Search research articles
Contact Us
Filters
Showing results (231-240 of 264) with videos related to
Page
of 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2024
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Talal El Zarif, Catherine B Meador, Xintao Qiu, et al.
Cell Metabolism
|
April 5, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Tommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cell Metabolism
|
February 25, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Tommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS<sup>G12C</sup> inhibitors
J M Riedl, F Fece de la Cruz, J J Lin, et al.
Nature Communications
|
May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Chendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Nature Biotechnology
|
February 12, 2020
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy
David G Millar, Rakesh R Ramjiawan, Kosuke Kawaguchi, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 264) with videos related to
Sort By:
Page
of 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 24, 2024
Detecting Small Cell Transformation in Patients with Advanced EGFR Mutant Lung Adenocarcinoma through Epigenomic cfDNA Profiling
Talal El Zarif, Catherine B Meador, Xintao Qiu, et al.
Cell Metabolism
|
April 5, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Tommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Cancer Discovery
|
December 13, 2022
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations
Alexander Drilon, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cell Metabolism
|
February 25, 2023
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
Tommy Weiss-Sadan, Maolin Ge, Makiko Hayashi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 6, 2025
Genomic landscape of clinically acquired resistance alterations in patients treated with KRAS<sup>G12C</sup> inhibitors
J M Riedl, F Fece de la Cruz, J J Lin, et al.
Nature Communications
|
May 2, 2025
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Chendi Li, Mohammed Usman Syed, Anahita Nimbalkar, et al.
Cancer Discovery
|
April 14, 2018
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer
Satoshi Yoda, Jessica J Lin, Michael S Lawrence, et al.
Cancer Discovery
|
September 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul, et al.
Cancer Discovery
|
August 17, 2019
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
Anna F Farago, Beow Y Yeap, Marcello Stanzione, et al.
Nature Biotechnology
|
February 12, 2020
Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy
David G Millar, Rakesh R Ramjiawan, Kosuke Kawaguchi, et al.
Page
of 27